Introduction: despite neurofilaments are mainly expressed in large caliber myelinated axons, recent evidence supports the existence of a specific synaptic pool, where neurofilament light chain (NfL) has been proposed to stabilize NMDAR at post-synaptic membrane through a direct interaction with the GluN1 subunit. Here, we assessed the expression and synaptic abundance of neurofilaments and their interaction with NMDAR in experimental alpha-synucleinopathy models. Methods: we used confocal imaging and biochemical approaches to confirm NMDAR-NfL interaction at synapses. Western blotting in purified fractions and Co-IP were then performed to assess synaptic neurofilaments expression and GluN1-NfL interaction in (i) alpha-synuclein pre-formed fibrils- (alpha-syn PFF) treated hippocampal neuronal cultures and (ii) mice intrastriatally injected with alpha-syn-PFF. Results: we identified the existence of a direct protein-protein interaction between NMDAR and NfL endogenously expressed in neurons. Our findings showed increased striatal GluN1-NfL interaction levels at early phases of alpha-syn PFF-treated mice compared to controls (NfL/GluN1 optical density: alpha-syn PFF 0.71 +/- 0.04; controls 0.48 +/- 0.03; t(9) = 4.67; p = 0.001). In agreement with this observation, we found that NfL levels are increased in striatal post-synaptic fractions of alpha-syn PFF-treated mice (normalized optical density: alpha-syn PFF 1.86 +/- 0.14; controls 1.34 +/- 0.13 t(18) = 2.70; p = 0.015). Conclusions: our results demonstrate alterations of striatal synaptic neurofilament pool in alpha-synucleinopathy models and open the way to further investigations evaluating a potential role of neurofilaments dysregulation in explaining glutamatergic synaptic dysfunction observed in alpha-synucleinopathies such as Parkinson's disease.

Synaptic neurofilaments and GluN1-NfL interaction in experimental models of α-synucleinopathies / A. Imarisio, E. Ferrari, A. Pilotto, M. Di Luca, A. Padovani, F. Gardoni. - In: NEURODEGENERATIVE DISEASES. - ISSN 1660-2854. - 22:1(2022 Nov), pp. 7-14. [10.1159/000526376]

Synaptic neurofilaments and GluN1-NfL interaction in experimental models of α-synucleinopathies

E. Ferrari
Secondo
;
M. Di Luca;F. Gardoni
Ultimo
2022

Abstract

Introduction: despite neurofilaments are mainly expressed in large caliber myelinated axons, recent evidence supports the existence of a specific synaptic pool, where neurofilament light chain (NfL) has been proposed to stabilize NMDAR at post-synaptic membrane through a direct interaction with the GluN1 subunit. Here, we assessed the expression and synaptic abundance of neurofilaments and their interaction with NMDAR in experimental alpha-synucleinopathy models. Methods: we used confocal imaging and biochemical approaches to confirm NMDAR-NfL interaction at synapses. Western blotting in purified fractions and Co-IP were then performed to assess synaptic neurofilaments expression and GluN1-NfL interaction in (i) alpha-synuclein pre-formed fibrils- (alpha-syn PFF) treated hippocampal neuronal cultures and (ii) mice intrastriatally injected with alpha-syn-PFF. Results: we identified the existence of a direct protein-protein interaction between NMDAR and NfL endogenously expressed in neurons. Our findings showed increased striatal GluN1-NfL interaction levels at early phases of alpha-syn PFF-treated mice compared to controls (NfL/GluN1 optical density: alpha-syn PFF 0.71 +/- 0.04; controls 0.48 +/- 0.03; t(9) = 4.67; p = 0.001). In agreement with this observation, we found that NfL levels are increased in striatal post-synaptic fractions of alpha-syn PFF-treated mice (normalized optical density: alpha-syn PFF 1.86 +/- 0.14; controls 1.34 +/- 0.13 t(18) = 2.70; p = 0.015). Conclusions: our results demonstrate alterations of striatal synaptic neurofilament pool in alpha-synucleinopathy models and open the way to further investigations evaluating a potential role of neurofilaments dysregulation in explaining glutamatergic synaptic dysfunction observed in alpha-synucleinopathies such as Parkinson's disease.
Neurofilaments; NMDA receptor; Parkinson’s disease; Synaptic dysfunction; Striatum
Settore BIO/14 - Farmacologia
PRIN201719FGARD_01 - Role of alpha-synuclein and LRRK2 in Levodopa-induced dyskinesia - GARDONI, FABRIZIO - PRIN2017 - PRIN bando 2017 - 2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
NDD526376.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 486.84 kB
Formato Adobe PDF
486.84 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/945283
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact